Longitudinal cerebral blood flow and amyloid deposition: An emerging pattern?

Journal of Nuclear Medicine

Volumn 49, Issue 9, 2008, Pages 1465-1471

  Sojkova, Jitka ^a,b   Beason Held, Lori ^a   Zhou, Yun ^b   An, Yang ^a   Kraut, Michael A ^b   Ye, Weigo ^b   Ferrucci, Luigi ^a   Mathis, Chester A ^c   Klunk, William E ^c   Wong, Dean F ^b,d   Resnick, Susan M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aging; CBF; Longitudinal; PIB; Positron emission tomography

Indexed keywords

AMYLOID; CONTRAST MEDIUM; PITTSBURGH COMPOUND B C11; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN BLOOD FLOW; CAUDATE NUCLEUS; CINGULATE GYRUS; CLUSTER ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MESENCEPHALON; PARIETAL LOBE; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BLOOD FLOW VELOCITY; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE;

EID: 51349166667     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.051946     Document Type: Article

References (38)

1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.
2. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol. 2005;62:1160-1163.
3. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446-452.
4. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68:1718-1725.
5. 11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603-1606.
6. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. May 10, 2007 [Epub ahead of print].
7. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005;62:758-765.
8. Driscoll I, Resnick SM, Troncoso JC, An Y, O'Brien R, Zonderman AB. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60:688-695.
9. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709-7717.
10. Niwa K, Carlson GA, Iadecola C. Exogenous Aβ1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J Cereb Blood Flow Metab. 2000;20:1659-1668.
11. Johnson KA, Moran EK, Becker JA, Blacker D, Fischman AJ, Albert MS. Single photon emission computed tomography perfusion differences in mild cognitive impairment. J Neurol Neurosurg Psychiatry. 2007;78:240-247.
12. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431-434.
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
14. Resnick SM, Goldszal AF, Davatzikos C, et al. One-year age changes in MRI brain volumes in older adults. Cereb Cortex. 2000;10:464-472.
15. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
16. Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 2000;54:2072-2077.
17. Zhou Y, Endres CJ, Brasic JR, Huang SC, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage. 2003;18:975-989.
18. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
19. 11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. Neuroimage. 2007;36:298-312.
20. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
21. Huang C, Wahlund LO, Almkvist O, et al. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage. 2003;19:1137-1144.
22. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology. 1998;50:1563-1571.
23. Perry RJ, Hodges JR. Attention and executive deficits in Alzheimer's disease: a critical review. Brain. 1999;122:383-404.
24. Scarmeas N, Habeck CG, Zarahn E, et al. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage. 2004;23:35-45.
25. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med. 2000;41:1155-1162.
26. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
27. 11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575-1580.
28. 18F]FDG PET study. Neurology. 2007;68:501-508.
29. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. July 19, 2006 [Epub ahead of print].
30. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003;9:907-913.
31. Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci. 2004;24:4535-4540.
32. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
33. Tong XK, Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience. 1999;92:163-175.
34. 1-42-amyloid peptide. Brain Res. 2001;912:128-136.
35. Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia. 2008;46:1624-1635.
36. Iacono D, O'Brien R, Resnick SM, et al. Neuronal hypertrophy in asymptomatic Alzheimer's disease. J Neuropathol Exp Neurol. 2008;67:578-589.
37. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke. 1994;25:318-327.
38. Kraut MA, Beason-Held LL, Elkins WD, Resnick SM. The impact of magnetic resonance imaging-detected white matter hyperintensities on longitudinal changes in regional cerebral blood flow. J Cereb Blood Flow Metab. 2008;28:190-197.